newsfilter
← Latest News
GlobeNewswire·

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

CNXUESTAINMDPCRXTELA
  • Conexeu Sciences (NASDAQ: CNXU) announced a preclinical partnership with the Wake Forest Institute for Regenerative Medicine (WFIRM) to evaluate its 3D-bioprinted B.R.E.A.S.T.™ tissue matrix.
  • The development program utilizes WFIRM's Integrated Tissue-Organ Printing System (iTOPS) to assess the matrix's durability, host tissue integration, & resorbability under physiological conditions.
  • Conexeu's proprietary CXU™ platform is designed as a scalable extracellular matrix solution targeting multiple markets including breast reconstruction, wound care, dental applications, body contouring, & veterinary medicine.
  • The company holds a clean intellectual property position with issued patents in the U.S., E.U., Japan, & Australia, & plans a 510(k) regulatory submission for its initial indication in early 2027.
  • Conexeu began trading on the Nasdaq on May 21, 2026, with 25,269,996 shares issued & outstanding, & H.C. Wainwright & Co. served as the exclusive financial advisor.
  • Competitor Establishment Labs (NASDAQ: ESTA) reported Q1 2026 revenue of $59.9 million (up 44.7% year-over-year) & surpassed five million Motiva® device sales globally.
  • Competitor InMode (NASDAQ: INMD) reported Q1 2026 GAAP revenue of $82.0 million (up 5% year-over-year) & appointed new leadership including Chairman Dr. Shlomo Nass.
  • Competitor Pacira BioSciences (NASDAQ: PCRX) reported Q1 2026 revenue of $177 million (up 5% year-over-year) & advanced its PCRX-201 gene therapy platform with FDA Regenerative Medicine Advanced Therapy designation.
  • Competitor TELA Bio (NASDAQ: TELA) reported Q1 2026 revenue of $19.1 million with international sales up 41% year-over-year & initiated the U.S. commercial launch of its OviTex® LTR hernia repair solution.
  • The regenerative medicine market is projected to grow from approximately $47.4 billion in 2025 to $230.4 billion by 2034, driving investor interest in Conexeu's technology.